MaxCyte Inc (MXCT) Ord USD0.01 (DI)
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
MaxCyte reports strong fourth quarter as full-year revenues fall
13 March 2024 12:04
(Sharecast News) - Cell engineering technology specialist MaxCyte reported total fourth quarter revenue of $15.7m on Wednesday, up 26% on the same period in 2022.
-
MaxCyte flags lower 2023 revenue, flat 2024 growth
5 March 2024 13:01
(Sharecast News) - Cell engineering technology specialist MaxCyte said in an update on Tuesday that it expected total 2023 revenue of between $41.1m and $41.3m, down from $44.3m in 2022.
-
MaxCyte flags uptick in total fourth-quarter revenue
9 January 2024 08:55
(Sharecast News) - Cell engineering company MaxCyte said on Tuesday that total fourth-quarter revenue was expected to be between $15.5m and $15.7m.
-
Maher Masoud starts as MaxCyte president, CEO
2 January 2024 11:25
(Sharecast News) - MaxCyte confirmed the appointment of Maher Masoud as its new president and chief executive officer on Tuesday, effective from 1 January.
-
MaxCyte announces new CEO, updates revenue guidance
12 December 2023 13:46
(Sharecast News) - Cell engineering technology specialist MaxCyte announced a significant chief executive transition on Tuesday and updated its revenue guidance for 2023.
-
MaxCyte joins Alliance for mRNA Medicines
16 November 2023 13:57
(Sharecast News) - Cell engineering company MaxCyte announced its membership in the Alliance for mRNA Medicines (AMM) as a founding member on Thursday.
-
MaxCyte lowers full-year guidance after weaker third quarter
5 October 2023 13:00
(Sharecast News) - Cell engineering specialist MaxCyte revised its full-year guidance downwards on Thursday based on its preliminary third-quarter revenue.
-
MaxCyte signs licence deal with Vittoria Biotherapeutics
10 July 2023 13:20
(Sharecast News) - MaxCyte announced a strategic platform licence agreement with Vittoria Biotherapeutics on Monday, granting Vittoria non-exclusive clinical and commercial rights to use MaxCyte's...
-
MaxCyte inks platform licensing deal with Lyell
6 July 2023 14:49
(Sharecast News) - Cell engineering platform technology company MaxCyte announced a strategic platform licence (SPL) agreement with Lyell Immunopharma - a clinical-stage T-cell reprogramming company - on...
-
MaxCyte revises guidance after weaker first quarter
11 May 2023 12:10
(Sharecast News) - Cell engineering specialist MaxCyte saw its shares slide on Thursday, after it updated its revenue guidance for the year on the back of its first quarter performance.
-
MaxCyte installs Douglas Swirsky as its new finance chief
28 March 2023 13:03
(Sharecast News) - Cell engineering technology company MaxCyte announced the appointment of Douglas Swirsky as its new chief financial officer on Tuesday.
-
MaxCyte expecting strong 2023 after decent results
16 March 2023 15:01
(Sharecast News) - Cell engineering specialist MaxCyte reported total revenue of $12.4m in the fourth quarter of 2022 on Thursday, making for an increase of 22% year-on-year.
Company announcements Announcements
-
Notice of Results
10 April 2024 13:05
Maxcyte (DI)
-
Total Voting Rights and Block Listing Return
3 April 2024 07:00
Maxcyte (DI)
-
Signing of Strategic Platform License
2 April 2024 13:05
Maxcyte (DI)
-
Exercise of options and PDMR dealing
2 April 2024 07:00
Maxcyte (DI)
-
Grant of Options, RSUs and PSUs and PDMR Dealing
20 March 2024 10:16
Maxcyte (DI)
-
Grant of Options, RSUs and PSUs and PDMR Dealing
20 March 2024 10:05
Maxcyte (DI)
-
Filing of form 10-K for FY ended December 31, 2023
13 March 2024 07:05
Maxcyte (DI)
-
Reports Q4 & FY 2023 Financial Results
13 March 2024 07:00
Maxcyte (DI)
-
TR-1: Notification of major holdings
6 March 2024 08:58
Maxcyte (DI)
-
Preliminary FY Results & 2024 Guidance
5 March 2024 07:00
Maxcyte (DI)
-
Total Voting Rights
1 March 2024 17:57
Maxcyte (DI)
-
Exercise of options and PDMR dealing
29 February 2024 09:21
Maxcyte (DI)
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.